ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 7
Jul.  2021
Turn off MathJax
Article Contents
Please cite this article as: Tersalvi G, Gasperetti A, Schiavone M, Dauw J, Gobbi C, Denora M, Krul JD, Cioffi GM, Mitacchione G, Forleo GB. Acute heart failure in elderly patients: a review of invasive and non-invasive management. J Geriatr Cardiol 2021; 18(7): 560−576. DOI: 10.11909/j.issn.1671-5411.2021.07.004
Citation: Please cite this article as: Tersalvi G, Gasperetti A, Schiavone M, Dauw J, Gobbi C, Denora M, Krul JD, Cioffi GM, Mitacchione G, Forleo GB. Acute heart failure in elderly patients: a review of invasive and non-invasive management. J Geriatr Cardiol 2021; 18(7): 560−576. DOI: 10.11909/j.issn.1671-5411.2021.07.004

Acute heart failure in elderly patients: a review of invasive and non-invasive management

doi: 10.11909/j.issn.1671-5411.2021.07.004
*The authors contributed equally to this manuscript
More Information
  • Acute heart failure (AHF) is a major cause of unplanned hospitalisations in the elderly and is associated with high mortality. Its prevalence has grown in the last years due to population aging and longer life expectancy of chronic heart failure patients. Although international societies have provided guidelines for the management of AHF in the general population, scientific evidence for geriatric patients is often lacking, as these are underrepresented in clinical trials. Elderly have a different risk profile with more comorbidities, disability, and frailty, leading to increased morbidity, longer recovery time, higher readmission rates, and higher mortality. Furthermore, therapeutic options are often limited, due to unfeasibility of invasive strategies, mechanical circulatory support and cardiac transplantation. Thus, the in-hospital management of AHF should be tailored to each patient’s clinical situation, cardiopulmonary condition and geriatric assessment. Palliative care should be considered in some cases, in order to avoid unnecessary diagnostics and/or treatments. After discharge, a strict follow-up through outpatient clinic or telemedicine is can improve quality of life and reduce rehospitalisation rates. The aim of this review is to offer an insight on current literature and provide a clinically oriented, patient-tailored approach regarding assessment, treatment and follow-up of elderly patients admitted for AHF.
  • loading
  • [1]
    Bleumink GS, Knetsch AM, Sturkenboom MCJM, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614−1619. doi: 10.1016/j.ehj.2004.06.038
    [2]
    Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135: e146−e603.
    [3]
    Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol 2014; 171: 368−376. doi: 10.1016/j.ijcard.2013.12.028
    [4]
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 18: 891−975. doi: 10.1002/ejhf.592
    [5]
    Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure. J Am Coll Cardiol 2019; 74: 1966−2011. doi: 10.1016/j.jacc.2019.08.001
    [6]
    Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health 2019; 4: e406−e420. doi: 10.1016/S2468-2667(19)30108-2
    [7]
    Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574−1585. doi: 10.1002/ejhf.813
    [8]
    Uemura Y, Shibata R, Takemoto K, et al. Prognostic Impact of the Preservation of Activities of Daily Living on Post-Discharge Outcomes in Patients With Acute Heart Failure. Circ J 2018; 82: 2793−2799. doi: 10.1253/circj.CJ-18-0279
    [9]
    Cleland JGF, McDonagh T, Rigby AS, et al. The national heart failure audit for England and Wales 2008–2009. Heart 2011; 97: 876−886. doi: 10.1136/hrt.2010.209171
    [10]
    Reeves GR, Whellan DJ, Patel MJ, et al. Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients ≥ 60 Years Hospitalized With Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure With Reduced and Preserved Left Ventricular Ejection Fraction. Am J Cardiol 2016; 117: 1953−1958. doi: 10.1016/j.amjcard.2016.03.046
    [11]
    Lainščak M, Milinković I, Polovina M, et al. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020; 22: 92−102. doi: 10.1002/ejhf.1645
    [12]
    Arrigo M, Jessup M, Mullens W, et al. Acute heart failure. Nat Rev Dis Primer 2020; 6: 16. doi: 10.1038/s41572-020-0151-7
    [13]
    Zile MR, Bennett TD, St. John Sutton M, et al. Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures. Circulation 2008; 118: 1433−1441. doi: 10.1161/CIRCULATIONAHA.108.783910
    [14]
    Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res 2019; 124: 1598−1617. doi: 10.1161/CIRCRESAHA.119.313572
    [15]
    Mogensen UM, Ersbøll M, Andersen M, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011; 13: 1216−1223. doi: 10.1093/eurjhf/hfr116
    [16]
    Metra M, Mentz RJ, Chiswell K, et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial: Acute heart failure in the elderly. Eur J Heart Fail 2015; 17: 109−118. doi: 10.1002/ejhf.207
    [17]
    Lorenzo M, de la Espriella R, Miñana G, et al. Clinical profile and 1-year clinical outcomes of super elderly patients admitted with acute heart failure. Eur J Intern Med 2020: S095362052030203X.
    [18]
    Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction in older adults. Heart Fail Clin 2017; 13: 485−502. doi: 10.1016/j.hfc.2017.02.005
    [19]
    Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65−75. doi: 10.1161/CIRCULATIONAHA.111.080770
    [20]
    Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297−3317. doi: 10.1093/eurheartj/ehz641
    [21]
    Claret P-G, Stiell IG, Yan JW, et al. Characteristics and outcomes for acute heart failure in elderly patients presenting to the ED. Am J Emerg Med 2016; 34: 2159−2166. doi: 10.1016/j.ajem.2016.08.015
    [22]
    Kulminski AM, Ukraintseva SV, Kulminskaya IV, et al. Cumulative Deficits Better Characterize Susceptibility to Death in Elderly People than Phenotypic Frailty: Lessons from the Cardiovascular Health Study: FRAILTY, CUMULATIVE DEFICITS, AND SURVIVAL. J Am Geriatr Soc 2008; 56: 898−903. doi: 10.1111/j.1532-5415.2008.01656.x
    [23]
    Teixeira A, Arrigo M, Tolppanen H, et al. Management of acute heart failure in elderly patients. Arch Cardiovasc Dis 2016; 109: 422−430. doi: 10.1016/j.acvd.2016.02.002
    [24]
    Huerta-Preciado J, Franco J, Formiga F, et al. Differential characteristics of acute heart failure in very elderly patients: the prospective RICA study. Aging Clin Exp Res 2020; 32: 1789−1799. doi: 10.1007/s40520-019-01363-8
    [25]
    Freund Y, Cachanado M, Delannoy Q, et al. Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: The ELISABETH Randomized Clinical Trial. JAMA 2020; 324: 1948. doi: 10.1001/jama.2020.19378
    [26]
    Lee DS, Lee JS, Schull MJ, et al. Prospective validation of the emergency heart failure mortality risk grade for acute heart failure: The ACUTE Study. Circulation 2019; 139: 1146−1156. doi: 10.1161/CIRCULATIONAHA.118.035509
    [27]
    Miró Ò, Rossello X, Gil V, et al. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. Ann Intern Med 2017; 167: 698. doi: 10.7326/M16-2726
    [28]
    Stiell IG, Perry JJ, Clement CM, et al. Prospective and Explicit Clinical Validation of the Ottawa Heart Failure Risk Scale, With and Without Use of Quantitative NT -pro BNP. Acad Emerg Med 2017; 24: 316−327. doi: 10.1111/acem.13141
    [29]
    Jia Q, Wang Y-R, He P, et al. Prediction model of in-hospital mortality in elderly patients with acute heart failure based on retrospective study. J Geriatr Cardiol 2017; 14: 669−678.
    [30]
    Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528−536. doi: 10.1093/eurjhf/hfr030
    [31]
    Gök G, Karadağ M, Sinan ÜY, et al. A new risk score to predict in-hospital mortality in elderly patients with acute heart failure: on behalf of the Journey HF-TR Study Investigators. Angiology 2020; 71: 948−954. doi: 10.1177/0003319720941758
    [32]
    Duflos C, Troude P, Strainchamps D, et al. Hospitalization for acute heart failure: the in-hospital care pathway predicts one-year readmission. Sci Rep 2020; 10: 10644. doi: 10.1038/s41598-020-66788-y
    [33]
    Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017; 69: 3042−3051. doi: 10.1016/j.jacc.2017.04.042
    [34]
    Ter Maaten JM, Valente MAE, Damman K, et al. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol 2015; 12: 184−192. doi: 10.1038/nrcardio.2014.215
    [35]
    Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 137−155. doi: 10.1002/ejhf.1369
    [36]
    Paneni F, Diaz Cañestro C, Libby P, et al. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol 2017; 69: 1952−1967.
    [37]
    Tersalvi G, Dauw J, Gasperetti A, et al. The value of urinary sodium assessment in acute heart failure. Eur Heart J Acute Cardiovasc Care 2021: 8.
    [38]
    Metra M, Cotter G, Senger S, et al. Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. Circ Heart Fail 2018; 11: e004644.
    [39]
    Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 2018; 137: 2016−2028. doi: 10.1161/CIRCULATIONAHA.117.030112
    [40]
    Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory–a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22: 584−603. doi: 10.1002/ejhf.1697
    [41]
    Kozhuharov N, Goudev A, Flores D, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC Randomized Clinical Trial. JAMA 2019; 322: 2292−2302. doi: 10.1001/jama.2019.18598
    [42]
    Marcantonio ER. Delirium in Hospitalized Older Adults. N Engl J Med 2017; 377: 1456−1466. doi: 10.1056/NEJMcp1605501
    [43]
    Mebazaa A, Motiejunaite J, Gayat E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 2018; 20: 332−341. doi: 10.1002/ejhf.991
    [44]
    Puymirat E, Fagon JY, Aegerter P, et al. Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Fail 2017; 19: 192−200. doi: 10.1002/ejhf.646
    [45]
    Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail 2019; 7: 1−12. doi: 10.1016/j.jchf.2018.06.011
    [46]
    Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 2018; 71: 201−230. doi: 10.1016/j.jacc.2017.11.025
    [47]
    Gayat E, Arrigo M, Littnerova S, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart Fail 2018; 20: 345−354. doi: 10.1002/ejhf.932
    [48]
    Seo W-W, Park JJ, Park HA, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open 2020; 10: e030514. doi: 10.1136/bmjopen-2019-030514
    [49]
    Colvin M, Sweitzer NK, Albert NM, et al. Heart Failure in non-caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee. J Card Fail 2015; 21: 674−693. doi: 10.1016/j.cardfail.2015.05.013
    [50]
    Gorodeski EZ, Goyal P, Hummel SL, et al. Domain management approach to heart failure in the geriatric patient. J Am Coll Cardiol 2018; 71: 1921−1936. doi: 10.1016/j.jacc.2018.02.059
    [51]
    Alviar CL, Miller PE, McAreavey D, et al. Positive pressure ventilation in the cardiac intensive care unit. J Am Coll Cardiol 2018; 72: 1532−1553. doi: 10.1016/j.jacc.2018.06.074
    [52]
    Nava S, Grassi M, Fanfulla F, et al. Non-invasive ventilation in elderly patients with acute hypercapnic respiratory failure: A randomised controlled trial. Age Ageing 2011; 40: 444−450. doi: 10.1093/ageing/afr003
    [53]
    Scala R. Challenges on non-invasive ventilation to treat acute respiratory failure in the elderly. BMC Pulm Med 2016; 16: 1−10. doi: 10.1186/s12890-015-0163-3
    [54]
    Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296−2304. doi: 10.1056/NEJMoa1210357
    [55]
    Forleo GB, De Martino G, Mantica M, et al. Clinical impact of catheter ablation in patients with asymptomatic atrial fibrillation: The IRON-AF (Italian Registry on NavX Atrial Fibrillation Ablation Procedures) study. Int J Cardiol 2013; 168: 3968−3970. doi: 10.1016/j.ijcard.2013.06.132
    [56]
    Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1242−1254. doi: 10.1002/ejhf.890
    [57]
    Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. Epub ahead of print November 13, 2020. DOI: 10.1161/CIRCHEARTFAILURE.120.006977.
    [58]
    Disdier Moulder MPA, Hendricks AK, Ou NN. Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take? Clin Cardiol 2020; 43: 137−144. doi: 10.1002/clc.23304
    [59]
    Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 230. doi: 10.1186/s12877-017-0621-2
    [60]
    Freeland KN, Thompson AN, Zhao Y, et al. Medication use and associated risk of falling in a geriatric outpatient population. Ann Pharmacother 2012; 46: 1188−1192. doi: 10.1345/aph.1Q689
    [61]
    Crentsil V, Ricks MO, Xue Q-L, et al. A pharmacoepidemiologic study of community-dwelling, disabled older women: Factors associated with medication use. Am J Geriatr Pharmacother 2010; 8: 215−224. doi: 10.1016/j.amjopharm.2010.06.003
    [62]
    Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc 2012; 60: 34−41. doi: 10.1111/j.1532-5415.2011.03772.x
    [63]
    Goyal P, Kneifati-Hayek J, Archambault A, et al. Prescribing patterns of heart failure-exacerbating medications following a heart failure hospitalization. JACC Heart Fail 2020; 8: 25−34. doi: 10.1016/j.jchf.2019.08.007
    [64]
    Sunaga T, Yokoyama A, Nakamura S, et al. Association of Potentially Inappropriate Medications With All-Cause Mortality in the Elderly Acute Decompensated Heart Failure Patients: Importance of Nonsteroidal Anti-Inflammatory Drug Prescription. Cardiol Res 2020; 11: 239−246. doi: 10.14740/cr1078
    [65]
    Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57−65.
    [66]
    Tersalvi G, Biasco L, Cioffi GM, et al. Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective. J Clin Med. Epub ahead of print 1 July 9, 2020. DOI: 10.3390/jcm9072064.
    [67]
    Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf 2017; 8: 273−297. doi: 10.1177/2042098617715381
    [68]
    Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol 2019; 73: 2584−2595.
    [69]
    O’Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. Expert Rev Clin Pharmacol 2020; 13: 15−22. doi: 10.1080/17512433.2020.1697676
    [70]
    Denny RM, Hummel SL. Heart failure medical management in 2020: searching for the right polypharmacy. Circ Heart Fail. Epub ahead of print November 13, 2020. DOI: 10.1161/CIRCHEARTFAILURE.120.007779.
    [71]
    Cermakova P, Lund LH, Fereshtehnejad S, et al. Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail 2015; 17: 612−619. doi: 10.1002/ejhf.222
    [72]
    Honda S, Nagai T, Sugano Y, et al. Prevalence, determinants, and prognostic significance of delirium in patients with acute heart failure. Int J Cardiol 2016; 222: 521−527. doi: 10.1016/j.ijcard.2016.07.236
    [73]
    Uthamalingam S, Gurm GS, Daley M, et al. Usefulness of acute delirium as a predictor of adverse outcomes in patients > 65 years of age with acute decompensated heart failure. Am J Cardiol 2011; 108: 402−408. doi: 10.1016/j.amjcard.2011.03.059
    [74]
    Vitale C, Jankowska E, Hill L, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 2019; 21: 1299−1305. doi: 10.1002/ejhf.1611
    [75]
    Verissimo P, Timenetsky KT, Casalaspo TJA, et al. High prevalence of respiratory muscle weakness in hospitalized acute heart failure elderly patients. PLoS ONE 2015; 10: 1−10.
    [76]
    Clark AL, Coats AJS, Krum H, et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial: Cachexia and beta blockers in chronic heart failure. J Cachexia Sarcopenia Muscle 2017; 8: 549−556. doi: 10.1002/jcsm.12191
    [77]
    Lenk K, Erbs S, Höllriegel R, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol 2012; 19: 404−411. doi: 10.1177/1741826711402735
    [78]
    von Haehling S. Casting the net broader to confirm our imaginations: the long road to treating wasting disorders: Editorial. J Cachexia Sarcopenia Muscle 2017; 8: 870−880. doi: 10.1002/jcsm.12256
    [79]
    Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998−1005. doi: 10.1016/j.jacc.2011.11.040
    [80]
    Sanders NA, Supiano MA, Lewis EF, et al. The frailty syndrome and outcomes in the TOPCAT trial: Frailty in HFpEF. Eur J Heart Fail 2018; 20: 1570−1577. doi: 10.1002/ejhf.1308
    [81]
    Hill E, Department of Geriatric Medicine, Glasgow Royal Infirmary, Glasgow, UK, Taylor J, et al. Chronic Heart Failure Care Planning: Considerations in Older Patients. Card Fail Rev 2017; 03: 46. doi: 10.15420/cfr.2016:15:2
    [82]
    Bielecka-Dabrowa A, Ebner N, Santos MR, et al. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail 2020: ejhf. 2011.
    [83]
    Dries DL, Exner D V., Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695−703. doi: 10.1016/S0735-1097(98)00297-6
    [84]
    Abualnaja S, Podder M, Hernandez AF, et al. Acute heart failure and atrial fibrillation: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. J Am Heart Assoc 2015; 4: e002092.
    [85]
    Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, et al. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail 2012; 5: 191−201. doi: 10.1161/CIRCHEARTFAILURE.111.965681
    [86]
    Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020: Aug 29.
    [87]
    Brembilla-Perrot B, Ferreira JP, Manenti V, et al. Predictors and prognostic significance of tachycardiomyopathy: Insights from a cohort of 1269 patients undergoing atrial flutter ablation. Eur J Heart Fail 2016; 18: 394−401. doi: 10.1002/ejhf.482
    [88]
    Purmah Y, Proietti M, Laroche C, et al. Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. Europace 2018; 20: 243−252. doi: 10.1093/europace/euw421
    [89]
    Fumagalli S, Said SAM, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF general pilot registry (EURObservational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol 2015; 1: 326−334. doi: 10.1016/j.jacep.2015.02.019
    [90]
    Hofmann R, Wimmer G, Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. Heart 2000; 84: 635. doi: 10.1136/heart.84.6.635
    [91]
    See I, Shehab N, Kegler SR, et al. Emergency department visits and hospitalizations for digoxin toxicity United States, 2005 to 2010. Circ Heart Fail 2014; 7: 28−34. doi: 10.1161/CIRCHEARTFAILURE.113.000784
    [92]
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129−2200m. doi: 10.1093/eurheartj/ehw128
    [93]
    Mohanty S, Di Biase L, Mohanty P, et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: Results from a randomized study (SPECULATE). Heart Rhythm 2015; 12: 477−483. doi: 10.1016/j.hrthm.2014.11.016
    [94]
    Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41: 1697−1702. doi: 10.1016/S0735-1097(03)00338-3
    [95]
    Lim KT, Davis MJE, Powell A, et al. Ablate and pace strategy for atrial fibrillation: Long-term outcome of AIRCRAFT trial. Europace 2007; 9: 498−505. doi: 10.1093/europace/eum091
    [96]
    Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000; 101: 1138−1144. doi: 10.1161/01.CIR.101.10.1138
    [97]
    Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018; 39: 3999−4008. doi: 10.1093/eurheartj/ehy555
    [98]
    Biteker M, Başaran Ö, Doğan V, et al. Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation: results from the real-life multicenter survey evaluating stroke study. J Am Geriatr Soc 2017; 65: 1684−1690. doi: 10.1111/jgs.14855
    [99]
    Oqab Z, Pournazari P, Sheldon RS. What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A systematic review and meta-analysis. J Atr Fibrillation 2018; 10: 1−5.
    [100]
    Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151−156. doi: 10.1093/ageing/afl129
    [101]
    Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: Evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62: 857−864. doi: 10.1111/jgs.12799
    [102]
    Proietti R, AlTurki A, Di Biase L, et al. Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis. J Cardiovasc Electrophysiol 2019; 30: 468−478. doi: 10.1111/jce.13822
    [103]
    Dillinger JG, Aleil B, Cheggour S, et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Arch Cardiovasc Dis 2018; 111: 85−94. doi: 10.1016/j.acvd.2017.04.008
    [104]
    Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773−778. doi: 10.1016/j.amjmed.2012.01.033
    [105]
    Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J 2018; 39: 453−460. doi: 10.1093/eurheartj/ehx579
    [106]
    Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J 2019; 40: 2327−2335. doi: 10.1093/eurheartj/ehz304
    [107]
    Chen J, Hocini M, Larsen TB, et al. Clinical management of arrhythmias in elderly patients: Results of the European Heart Rhythm Association survey. Europace 2014; 17: 314−317.
    [108]
    Aronow WS. Treatment of ventricular arrhythmias in the elderly. Cardiol Rev 2009; 17: 136−146. doi: 10.1097/CRD.0b013e3181a270f8
    [109]
    Clark AL, Cherif M, McDonagh TA, et al. In-hospital worsening heart failure: a clinically relevant endpoint?: In-hospital worsening heart failure. ESC Heart Fail 2018; 5: 9−18. doi: 10.1002/ehf2.12195
    [110]
    Koller K, Rockwood K. Frailty in older adults: implications for end-of-life care. Cleve Clin J Med 2013; 80: 168−174. doi: 10.3949/ccjm.80a.12100
    [111]
    Alqahtani F, Balla S, Almustafa A, et al. Utilization of palliative care in patients hospitalized with heart failure: A contemporary national perspective. Clin Cardiol 2019; 42: 136−142. doi: 10.1002/clc.23119
    [112]
    Cleland J, Dargie H, Hardman S, et al. National heart failure audit: April 2012-March 2013. London: National Institute for Cardiovascular Outcomes Research; 2013.
    [113]
    Lagu T, Pekow PS, Shieh M-S, et al. Validation and comparison of seven mortality prediction models for hospitalized patients with acute decompensated heart failure. Circ Heart Fail. Epub ahead of print August 9, 2016. DOI: 10.1161/CIRCHEARTFAILURE.115.002912.
    [114]
    Collins SP, Jenkins CA, Harrell FE, et al. Identification of emergency department patients with acute heart failure at low risk for 30-day adverse events. JACC Heart Fail 2015; 3: 737−747. doi: 10.1016/j.jchf.2015.05.007
    [115]
    Asano R, Abshire M, Dennison-Himmelfarb C, et al. Barriers and facilitators to a ‘good death’ in heart failure: An integrative review. Collegian 2019; 26: 651−665. doi: 10.1016/j.colegn.2019.09.010
    [116]
    Beattie JM, Higginson IJ, McDonagh TA. Palliative Care in Acute Heart Failure. Curr Heart Fail Rep 2020; 17: 424−437. doi: 10.1007/s11897-020-00494-8
    [117]
    Nizamic T, Murad MH, Allen LA, et al. Ambulatory inotrope infusions in advanced heart failure. JACC Heart Fail 2018; 6: 757−767. doi: 10.1016/j.jchf.2018.03.019
    [118]
    Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol 2014; 11: 329−337.
    [119]
    Matsushita K, Sakata K, Satoh T, et al. Estimated pulmonary artery systolic pressure and mortality in older-elderly heart failure patients. J Am Geriatr Soc 2019; 67: 323−328. doi: 10.1111/jgs.15663
    [120]
    Mueller C, Bally K, Buser M, et al. Roadmap for the treatment of heart failure patients after hospital discharge: an interdisciplinary consensus paper. Swiss Med Wkly 2020; 150: w20159.
    [121]
    Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716−1722. doi: 10.1001/jama.2010.533
    [122]
    Zsilinszka R, Mentz RJ, DeVore AD, et al. Acute Heart Failure: Alternatives to Hospitalization. JACC Heart Fail 2017; 5: 329−336. doi: 10.1016/j.jchf.2016.12.014
    [123]
    Severino P, D’Amato A, Saglietto A, et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail 2020; 7: 4182−4188. doi: 10.1002/ehf2.13043
    [124]
    Tersalvi G, Winterton D, Cioffi GM, et al. Telemedicine in Heart Failure During COVID-19: A Step Into the Future. Front Cardiovasc Med 2020; 7: 612818. doi: 10.3389/fcvm.2020.612818
    [125]
    Schiavone M, Gobbi C, Biondi-Zoccai G, et al. Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. J Clin Med 2020; 9: 1683. doi: 10.3390/jcm9061683
    [126]
    Schiavone M, Gasperetti A, Mancone M, et al. Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience. Int J Cardiol 2021; 323: 276−280. doi: 10.1016/j.ijcard.2020.09.001
    [127]
    Viecca M, Radovanovic D, Forleo GB, et al. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res 2020; 158: 104950.
    [128]
    Schiavone M, Gasperetti A, Mancone M, et al. Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease. J Clin Med 2020; 9: 3263. doi: 10.3390/jcm9103263
    [129]
    Gasperetti A, Biffi M, Duru F, et al. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. EP Eur 2020; 22: 1855−1863.
    [130]
    O’Connell TF, Bradley CJ, Abbas AE, et al. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. JACC Clin Electrophysiol 2021; 7: 16−25. doi: 10.1016/j.jacep.2020.07.016
    [131]
    Mitacchione G, Schiavone M, Gasperetti A, et al. Ventricular tachycardia storm management in a COVID-19 patient: a case report. Eur Heart J Case Rep 2020; 4: 1−6.
    [132]
    Gorodeski EZ, Moennich LA, Riaz H, et al. Virtual Versus In-Person Visits and Appointment No-Show Rates in Heart Failure Care Transitions. Circ Heart Fail 2020; 13: e007119.
    [133]
    Tersalvi G, Vicenzi M, Kirsch K, et al. Structured telephone support programs in chronic heart failure may be affected by a learning curve: J Cardiovasc Med 2020; 21: 231–237.
    [134]
    Scott Kruse C, Karem P, Shifflett K, et al. Evaluating barriers to adopting telemedicine worldwide: A systematic review. J Telemed Telecare 2018; 24: 4−12. doi: 10.1177/1357633X16674087
    [135]
    Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42: 17−96. doi: 10.1093/eurheartj/ehaa605
    [136]
    Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019; 1: CD003331.
    [137]
    Blumenthal JA, Babyak MA, O’Connor C, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA 2012; 308: 465−474.
    [138]
    Flynn KE, Piña IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301: 1451−1459. doi: 10.1001/jama.2009.457
    [139]
    Theou O, Stathokostas L, Roland KP, et al. The Effectiveness of Exercise Interventions for the Management of Frailty: A Systematic Review. J Aging Res 2011; 2011: 1−19.
    [140]
    Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2016; 315: 36. doi: 10.1001/jama.2015.17346
    [141]
    Fleg JL, Cooper LS, Borlaug BA, et al. Exercise training as therapy for heart failure: current status and future directions. Circ Heart Fail 2015; 8: 209−220. doi: 10.1161/CIRCHEARTFAILURE.113.001420
    [142]
    Schopfer DW, Forman DE. Growing relevance of cardiac rehabilitation for an older population with heart failure. J Card Fail 2016; 22: 1015−1022. doi: 10.1016/j.cardfail.2016.10.010
    [143]
    Beatty AL, Truong M, Schopfer DW, et al. Geographic Variation in Cardiac Rehabilitation Participation in Medicare and Veterans Affairs Populations: Opportunity for Improvement. Circulation 2018; 137: 1899−1908. doi: 10.1161/CIRCULATIONAHA.117.029471
    [144]
    Golwala H, Pandey A, Ju C, et al. Temporal trends and factors associated with cardiac rehabilitation referral among patients hospitalized with heart failure: findings from get with The Guidelines-Heart Failure Registry. J Am Coll Cardiol 2015; 66: 917−926. doi: 10.1016/j.jacc.2015.06.1089
    [145]
    Kubo I, Izawa KP, Kajisa N, et al. Factors delaying the progress of early rehabilitation of elderly Japanese patients with heart failure. Aging Clin Exp Res 2020; 32: 399−406. doi: 10.1007/s40520-019-01213-7
    [146]
    Reeves GR, Whellan DJ, Duncan P, et al. Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. Am Heart J 2017; 185: 130−139. doi: 10.1016/j.ahj.2016.12.012
    [147]
    Collins SP, Pang PS. ACUTE Heart Failure Risk Stratification: A Step Closer to the Holy Grail? Circulation 2019; 139: 1157−1161. doi: 10.1161/CIRCULATIONAHA.118.038472
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Article Metrics

    Article views (711) PDF downloads(116) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return